Core Viewpoint - Profound Medical Corp. is set to announce its second quarter 2025 financial results on August 14, 2025, and will host a conference call to discuss these results and business developments [1][2]. Company Overview - Profound Medical Corp. is a commercial-stage medical device company focused on developing and marketing customizable, incision-free therapies for the ablation of diseased tissue [3]. Product Offerings - The company is commercializing TULSA-PRO, a technology that integrates real-time MRI, AI-enhanced planning, and robotically-driven transurethral ultrasound for the treatment of prostate diseases. The TULSA procedure is designed to preserve urinary continence and sexual function while effectively targeting prostate tissue [4]. - TULSA is a single-session, incision-free procedure that operates at temperatures of 55-57°C, with no associated bleeding or hospital stay required, allowing for quick recovery [4]. - Profound is also marketing Sonalleve, a therapeutic platform approved for treating uterine fibroids and palliative pain from bone metastases. It has received CE marking and FDA approval under a Humanitarian Device Exemption for specific treatments [5].

Core Insights - Profound Medical Corp. is a commercial-stage medical device company focused on customizable, incision-free therapies for ablation of diseased tissue [3] Company Overview - Profound Medical is commercializing TULSA-PRO®, a technology that integrates real-time MRI, robotically-driven transurethral ultrasound, and closed-loop temperature feedback control for prostate disease treatment [4] - The TULSA procedure is designed to treat a range of prostate conditions, including low-, intermediate-, and high-risk prostate cancer, benign prostatic hyperplasia (BPH), and salvage therapy for radio-recurrent localized prostate cancer [4] - TULSA is a single-session procedure that preserves urinary continence and sexual function while effectively targeting prostate tissue through precise heating [4] - Profound is also commercializing Sonalleve®, a therapeutic platform for treating uterine fibroids and palliative pain from bone metastases, with approvals in multiple regions including CE marking and FDA clearance [5] Upcoming Events - Management will present a business update at the 2025 Bloom Burton & Co. Healthcare Investor Conference on May 6, 2025 [1] - The presentation will be available for live broadcast and archived on the company's website [2]